Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Sep 4:8:1185-94.
doi: 10.2147/PPA.S66619. eCollection 2014.

Effects of a pharmaceutical care model on medication adherence and glycemic control of people with type 2 diabetes

Wen Wei Chung  1 , Siew Siang Chua  2 , Pauline Siew Mei Lai  3 , Siew Pheng Chan  4
Affiliations

Effects of a pharmaceutical care model on medication adherence and glycemic control of people with type 2 diabetes

Wen Wei Chung et al. Patient Prefer Adherence. .

Abstract

Background: Diabetes mellitus is a lifelong chronic condition that requires self-management. Lifestyle modification and adherence to antidiabetes medications are the major determinants of therapeutic success in the management of diabetes.

Purpose: To assess the effects of a pharmaceutical care (PC) model on medication adherence and glycemic levels of people with type 2 diabetes mellitus.

Patients and methods: A total of 241 people with type 2 diabetes were recruited from a major teaching hospital in Malaysia and allocated at random to the control (n=121) or intervention (n=120) groups. Participants in the intervention group received PC from an experienced pharmacist, whereas those in the control group were provided the standard pharmacy service. Medication adherence was assessed using the Malaysian Medication Adherence Scale, and glycemic levels (glycated hemoglobin values and fasting blood glucose [FBG]) of participants were obtained at baseline and after 4, 8, and 12 months.

Results: At baseline, there were no significant differences in demographic data, medication adherence, and glycemic levels between participants in the control and intervention groups. However, statistically significant differences in FBG and glycated hemoglobin values were observed between the control and intervention groups at months 4, 8, and 12 after the provision of PC (median FBG, 9.0 versus 7.2 mmol/L [P<0.001]; median glycated hemoglobin level, 9.1% versus 8.0% [P<0.001] at 12 months). Medication adherence was also significantly associated with the provision of PC, with a higher proportion in the intervention group than in the control group achieving it (75.0% versus 58.7%; P=0.007).

Conclusion: The provision of PC has positive effects on medication adherence as well as the glycemic control of people with type 2 diabetes. Therefore, the PC model used in this study should be duplicated in other health care settings for the benefit of more patients with type 2 diabetes.

Keywords: glycemic control; medication adherence; pharmaceutical care; type 2 diabetes mellitus.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Comparison of FBG between control and intervention groups over time (shown as median in the graph). Notes: z-value, Mann–Whitney U-test, *statistically significant at P<0.05; **P<0.01. Abbreviations: FBG, fasting blood glucose; C, control group; I, intervention group; n, number of participants in each group.
Figure 2
Figure 2
Comparison of HbA1c values between control and intervention groups over time (shown as median in the graph). Notes: z-value, Mann–Whitney U-test, *statistically significant at P<0.05; **P<0.01. Abbreviations: HbA1c, glycated hemoglobin; C, control group; I, intervention group; n, number of participants in each group.
See this image and copyright information in PMC

References

    1. World Health Organization . Adherence to Long-term Therapies: Evidence for Action. Geneva: World Health Organization; 2003. [Accessed June 24, 2013]. Available from: http://www.who.int/chp/knowledge/publications/adherence_report/en/
    1. International Diabetes Federation IDF Diabetes Atlas. 6th ed. [Accessed: June 15, 2013]. Available from: http://www.idf.org/sites/default/files/EN_6E_Atlas_Full_0.pdf.
    1. Letchuman GR, Wan Nazaimoon WM, Wan Mohamad WB, et al. Prevalence of diabetes in the Malaysian National Health Morbidity Survey III 2006. Med J Malaysia. 2010;65(3):173–179. Available from http://www.e-mjm.org/2010/v65n3/Diabetes.pdf. Accessed August 11, 2014. - PubMed
    1. Mustapha F, Omar Z, Mihat O, et al. Addressing non-communicable diseases in Malaysia: an integrative process of systems and community. BMC Public Health. 2014;14(Suppl 2):S4. - PMC - PubMed
    1. Clifford RM, Davis WA, Batty KT, Davis TM, Fremantle Diabetes Study Effect of a pharmaceutical care program on vascular risk factors in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care. 2005;28(4):771–776. - PubMed

LinkOut - more resources